| Property | Value |
|---|
|
?:abstract
|
-
A recent study by Sies and Parnham expanded on the therapeutic potential of Epselen, an organoselenium compound, as an inhibitor of SARS-CoV-2’s main protease. In this study, using an unbiased, data driven bioinformatic screening of two independently extracted SARS-CoV-2 – induced host gene signatures confirms Selenium as a potential drug candidate. This pathway based approach adds transcriptomic evidence complimenting the protein-centered rationale expanded on by the authors. Given that aside from host – protein interactions, antisense transcript mRNA-mRNA interactions have been demonstrated to occur at selenocysteine related insertions in RNA viruses, transcriptomic-level evidence offer unique insight into viral lifecycles. Furthermore, the pathways identified from these two selenium associated signatures provide further insight into the perturbations of selenium metabolism introduced by SARS-CoV-2 during its lifecycle.
|
|
?:creator
|
|
|
?:doi
|
-
10.1016/j.freeradbiomed.2020.07.014
|
|
?:doi
|
|
|
?:journal
|
|
|
?:license
|
|
|
?:pdf_json_files
|
-
document_parses/pdf_json/78b3d579578aa398da4844bbc27c30fd0d9dfd7c.json
|
|
?:pmc_json_files
|
-
document_parses/pmc_json/PMC7361041.xml.json
|
|
?:pmcid
|
|
|
?:pmid
|
|
|
?:pmid
|
|
|
?:publication_isRelatedTo_Disease
|
|
|
?:sha_id
|
|
|
?:source
|
|
|
?:title
|
-
Selenium – associated gene signatures within the SARS-CoV-2 – host genomic interaction interface
|
|
?:type
|
|
|
?:year
|
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}